SHIMIZU Kyoko    Department   Other, Other    Position
Article types	Original article
Language	English
Peer review	Non peer reviewed
Title	Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials.
Journal	Formal name：Pancreas Abbreviation：Pancreas ISSN code：15364828/08853177
Domestic / Foregin	Foregin
Volume, Issue, Page	50(7),pp.965-971
Author and coauthor	Kobayashi Satoshi, Ueno Makoto, Ogawa Gakuto, Fukutomi Akira, Ikeda Masafumi, Okusaka Takuji, Sato Tosiya, Ito Yoshinori, Kadota Tomohiro, Ioka Tatsuya, Sugimori Kazuya, Sata Naohiro, Nakamori Shoji, Shimizu Kyoko, Mizuno Nobumasa, Ishii Hiroshi, Furuse Junji
Publication date	2021/08
Summary	OBJECTIVES:S-1 monotherapy with concurrent radiotherapy (RT) is a standard of care for patients with locally advanced pancreatic cancer (LAPC). Although renal dysfunction increases S-1 monotherapy toxicity, its effect in S-1 with concurrent RT remains unknown. We evaluated the effect of renal function on the safety of S-1 with RT for LAPC.METHODS:We performed an integrated exploratory post hoc analysis of data from 2 prospective studies (JCOG1106 and LAPC-S1RT), where patients with LAPC received RT (50.4 Gy/28 fraction for 5.5 weeks) and concurrent S-1 (40 mg/m2 per dose, twice daily on the day of irradiation). We split the patients into high creatinine clearance (CCr; ≥80 mL/min) and low CCr (<80 mL/min) groups and compared the findings to determine treatment safety.RESULTS:The high and low CCr groups showed a median of 97.5 (range, 80.0-194.6) and 64.4 (range, 50.0-78.3) mL/min, respectively. The low CCr group presented more adverse reactions (ARs) of grade 3 or higher and gastrointestinal ARs of grade 2 or higher than the high CCr group (30.8% vs 15.8% and 51.9% vs 36.8%).CONCLUSIONS:The incidence of ARs associated with concurrent S-1 and RT increases in patients with low CCr; therefore, ARs should be duly considered in such patients.
DOI	10.1097/MPA.0000000000001879
PMID	34629456